| DB ID | MyCo_1566 |
| Title | Evaluation of Aspergillus IgG, IgM antibody for diagnosing in chronic pulmonary aspergillosis: A prospective study from a single center in China |
| Year | 2019 |
| PMID | 31008929 |
| Fungal Diseases involved | Chronic pulmonary aspergillosis |
| Associated Medical Condition | None |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | This was a prospective study and was approved by the Ethics Committee of Beijing Chao-yang Hospital, Capital Medical University. All the enrolled patients had signed the informed consent. |
| Site of Infection | Lungs |
| Opportunistic invasive | Opportunistic |
| Sample type | Body fluid |
| Sample source | Blood |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | Aspergillus specific IgG |
| Biomarker Full Name | Aspergillus specific Immunoglobulin G |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | China |
| Cohort | The patients selected were those who visited the outpatient department and/or were hospitalized in the Beijing Chao-yang Hospital, Capital Medical University, due to cough, hemoptysis. The patients were recruited from May 2016 to April 2018. The patient inclusion criteria were as follows: Patients with lesions on chest computed tomography, such as sarcoidosis, cavity, fibrosis, and aspergilloma; patients with Aspergillus detection in lower respiratory tract samples; patients with suspicion of CPA as demonstrated by clinical diagnosis. The exclusion criteria were the following: Patients with severe immune deficiency, namely agranulocytosis, receptor receiving allogeneic hematopoietic stem cell transplantation, long-term administration of large dose of steroid hormone, administration of T cells immunosuppressor in the past 90 days, severe hereditary immunodeficiency disease, and acquired immune deficiency syndrome. All the patients provided the complete clinical information required for the conduct of the study. A total of 144 blood samples were collected for the detection of Aspergillus-specific IgG, IgM. In the cases selected into the study, there were 79 male and 65 female with an average age of (56.74± 15.67). In these cases, there were 22 cases with tuberculosis, 20 cases with bronchiectasis, 19 cases with chronic obstructive pulmonary disease (COPD), 7 cases with pulmonary sarcoidosis, 6 cases with pulmonary fibrosis, 4 cases with pneumoconiosis, 3 cases with lung tumor, 1 case with pulmonary vasculitis, and 1 case with nontuberculous mycobacterium pulmonary disease (6 cases coexist 2 kinds of diseases). |
| Cohort No. | 144 |
| Age Group | None |
| P Value | p < .01 |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Chronic pulmonary aspergillosis (CPA) is a slowly progressing pulmonary fungal infectious disease caused by Aspergillus. Approximately 3,000,000 people suffer from CPA worldwide, and the 5-year survival rate is estimated at 50%.. The onset of CPA is insidious, and the diagnosis is difficult. However, the early-stage diagnosis of CPA and the intervention therapy can significantly reduce the fatality of CPA. Therefore, a new effective serological marker is considered important for the confirmation of early-stage intervention. In 2016, the European Respiratory Society and the European Society of Clinical Microbiology and Infectious Diseases issued the first CPA guideline, which confirmed the value and significance of the use of Aspergillusspecific IgG for CPA diagnosis. |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | A fumigate IgG, IgM antibody quantitative detection ELISA kit (Dynamiker, China, LOT No. 160801). |
| Assay Data | None |
| Validation Techniques used | ELISA |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
